$894 Million Settlement Against Pfizer for Bextra and Celebrex

What Happened? The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the […]

October 17, 2008

What Happened?

The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the United States and represented approximately 400 claimants. In 2005, Pfizer withdrew Bextra from the market, while Celebrex remained, but with a required Black Box safety warning regarding the risk of heart attacks and strokes.

How Was the Settlement Structured?

Seeger Weiss LLP founding partner Christopher A. Seeger, a member of the Plaintiffs’ Steering Committee in the Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, helped to shape the $894 million settlement which was announced by Pfizer on October 17, 2008.

In total, there were several thousand lawsuits filed against Pfizer because of Bextra and Celebrex related injuries and deaths. The settlement figure announced was split up to deal with the various claims that were brought against Pfizer:

  • $745 million went toward personal-injury lawsuits;
  • $60 million went to states regarding the Bextra marketing claims; and
  • $89 million was allocated to resolve the consumer-fraud cases.

What is the Current Status of Bextra and Celebrex Lawsuits?

A Securities Class Action Against Pfizer Settled for $486 Million

In 2016, a related securities class action lawsuit filed by investors in 2004, was settled for $486 million. The investors claimed that Pfizer concealed information regarding studies of Bextra and Celebrex, that demonstrated the drugs might increase the risk of heart attacks and strokes. Once the studies were released to the public, and Bextra was pulled from the market, Pfizer’s share price dropped, and investors suffered losses.

Related News

June 12, 2025
Seeger Weiss and Partners Recognized in the Chambers 2025 USA Guide

Seeger Weiss is proud to announce that the firm—alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya—has been recognized in the newly released Chambers 2025 USA Guide. This marks the fifth consecutive year that Seeger Weiss has been recognized by Chambers USA. For over three decades, Chambers has been a trusted authority in […]

Read More
June 10, 2025
Ten Seeger Weiss Attorneys Named to Lawdragon’s 2025 500 Leading Plaintiff Financial Lawyers List

We are proud to announce that ten Seeger Weiss attorneys have been selected to Lawdragon’s 2025 Leading Plaintiff Financial Lawyers guide list, which honors attorneys who represent plaintiffs in complex financial litigation. Congratulations to Parvin Aminolroaya, Christopher Ayers, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, Christopher Seeger, and Stephen […]

Read More
May 28, 2025
Seeger Weiss Establishes Fund at Bolch Judicial Institute to Defend the Judiciary and Honor Daniel Anderl

Seeger Weiss LLP, led by founding partner Christopher A. Seeger, has made a $500,000 donation to the Bolch Judicial Institute at Duke Law School to establish The Seeger Weiss/Daniel Anderl Memorial Fund, which will provide long-term, flexible funding for the Institute to support two critical areas of the legal system: defending judicial independence and advancing […]

Read More